In today’s session Medtronic PLC (MDT) registered an unusually high (677) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious MDT increase. With 677 contracts traded and 13614 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: MDT161216C00087500 closed last at: $0.75 or 38.9% up. About 2.42 million shares traded hands. Medtronic PLC (NYSE:MDT) has risen 10.77% since April 7, 2016 and is uptrending. It has outperformed by 5.99% the S&P500.
Medtronic PLC (NYSE:MDT) Ratings Coverage
Out of 17 analysts covering Medtronic (NYSE:MDT), 13 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 76% are positive. $102 is the highest target while $82 is the lowest. The $90.43 average target is 10.44% above today’s ($81.88) stock price. Medtronic has been the topic of 23 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The rating was upgraded by Evercore on Thursday, October 8 to “Buy”. Jefferies maintained Medtronic PLC (NYSE:MDT) rating on Friday, August 26. Jefferies has “Buy” rating and $100 price target. On Wednesday, June 1 the stock rating was downgraded by BTIG Research to “Neutral”. The firm earned “Buy” rating on Tuesday, September 22 by UBS. SunTrust initiated the stock with “Buy” rating in Monday, April 25 report. Credit Suisse reinitiated the shares of MDT in a report on Monday, August 10 with “Outperform” rating. The stock has “Hold” rating given by Jefferies on Friday, September 4. Guggenheim initiated the stock with “Neutral” rating in Thursday, June 9 report. As per Wednesday, June 1, the company rating was maintained by Wedbush. The stock of Medtronic PLC (NYSE:MDT) has “Buy” rating given on Thursday, June 2 by Deutsche Bank.
According to Zacks Investment Research, “Medtronic is the world’s leading medical technology company, pioneering device-based therapies that restore health, extend life and alleviate pain. Primary products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, among others. Medtronic operates its business in one reportable segment, that of manufacturing and selling device-based medical therapies. The company does business in more than 120 countries. The company’s product lines include cardiac rhythm management, neurological and spinal, vascular and cardiac surgery.”
Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.09, from 0.89 in 2016Q1. The ratio fall, as 60 funds sold all Medtronic PLC shares owned while 508 reduced positions. 93 funds bought stakes while 361 increased positions. They now own 1.03 billion shares or 1.89% more from 1.01 billion shares in 2016Q1.
Martingale Asset L P has invested 0.28% of its portfolio in Medtronic PLC (NYSE:MDT). Investec Asset Mngmt Ltd has 2.61M shares for 1.11% of their US portfolio. Profund Advsr Llc last reported 0.25% of its portfolio in the stock. Cornerstone Advisors owns 608 shares or 0.05% of their US portfolio. Mirae Asset Global Invs Limited last reported 272,935 shares in the company. Bradley Foster And Sargent Inc Ct has 225,405 shares for 0.88% of their US portfolio. Fukoku Mutual Life Ins Com holds 7,349 shares or 0.12% of its portfolio. Tudor Inv Corporation Et Al last reported 4,000 shares in the company. Parsons Capital Ri reported 43,129 shares or 0.44% of all its holdings. Mcrae Management has 4.31% invested in the company for 107,379 shares. Roffman Miller Pa has 199,128 shares for 2.83% of their US portfolio. Verition Fund Mngmt Limited Liability Company has 0.04% invested in the company for 3,338 shares. Perritt Mngmt holds 4,526 shares or 0.1% of its portfolio. Barnett And reported 235 shares or 0.01% of all its holdings. Sectoral Asset Mgmt has 425,333 shares for 3.81% of their US portfolio.
Medtronic Public Limited Company is a medical technology and services company. The company has a market cap of $113.15 billion. The Firm develops, makes and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. It has a 31.82 P/E ratio. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
MDT Company Profile
Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. The Company’s Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. The Company’s Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. The Company’s Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Another recent and important Medtronic PLC (NYSE:MDT) news was published by Investorplace.com which published an article titled: “Medtronic PLC (MDT) Stock Oozes Long-Term Strength” on November 02, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.